Colorectal cancer, a disease once predominantly diagnosed in older adults, is now making a startling appearance in younger individuals, as evidenced by the story of 30-year-old Spencer Laird. This shift in demographics highlights a pressing need for innovative treatment approaches, and immunotherapy is emerging as a promising candidate. Spencer's journey with cancer began at age 27 when he underwent surgery to remove a colon tumor. Two years later, the cancer returned with a vengeance, metastasizing to his lungs. Facing the grim reality of stage four cancer, Spencer and his wife, CarleyAnn, embarked on a quest for alternative treatments, ultimately finding hope in a clinical trial at Duke University. This trial, funded by Gateway for Cancer Research, is testing a combination of immunotherapy drugs, Botensilimab and Balstilimab (BOT/BAL).
The Duke Cancer Institute's team, led by medical oncologist Dr. Nicholas DeVito, is at the forefront of this groundbreaking research. DeVito explains that the rise in colorectal cancer among younger people is concerning, often presenting with more advanced-stage disease. Chemotherapy, the traditional treatment, has its limitations, causing systemic damage to both cancer cells and healthy cells, leading to severe side effects. In contrast, immunotherapy harnesses the body's immune system to target cancer cells, offering a more precise and potentially less harmful approach. Spencer's decision to participate in the clinical trial was a turning point, as he experienced a remarkable response to the immunotherapy treatment, with no need for chemotherapy.
The Duke team's efforts are not just about finding a cure; they are about transforming the patient experience. DeVito emphasizes the importance of infrastructure and collaboration in making these breakthroughs possible. The "learning loop" between bench research and clinical practice is vital, and federal research funding plays a crucial role in supporting such innovative care centers. By studying tumors, identifying biomarkers, and developing mouse models that mimic human disease, researchers can refine therapies and bring them to the bedside. Spencer's story serves as a powerful reminder of the potential of immunotherapy and the importance of clinical trials. His journey inspires others to consider participating in research, challenging the notion that cancer is an insurmountable death sentence. Instead, it highlights the transformative power of innovative treatments and the crucial role of research in offering hope and a second chance at life.
